Once-daily versus twice-daily levobunolol (0.5%) therapy. A crossover study.
The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (IOP). Modified diurnal curves were performed at four times for each study arm: baseline, day 1, day 14, and day 28. The mean diurnal corrected decrease in IOP from baseline ranged from 16% +/- 11% to 22% +/- 9% when the subjects were treated twice daily, and from 14% +/- 10% to 18% +/- 8% when the same subjects were treated once daily. At day 1, patients had a significantly greater IOP lowering after twice-daily therapy than after once-daily therapy (P less than 0.05). At 14 and 28 days, there was no clinically significant difference between the two treatment regimens. The results of our crossover study suggest that once-daily treatment with levobunolol (0.5%) is as effective as twice-daily treatment.
Derick
R J
RJ
Glaucoma Service, Wilmer Institute, Johns Hopkins Hospital, Baltimore, MD.
Robin
A L
AL
Tielsch
J
J
Wexler
J L
JL
Kelley
E P
EP
Stoecker
J F
JF
Novack
G D
GD
Coleman
A L
AL
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002940:Circadian Rhythm; D003430:Cross-Sectional Studies; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D002040:Levobunolol / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*
D002040:Levobunolol